We are live on ! Find out more
PRDS

Pardes Biosciences, Inc. Common Stock
PRDS

Delisted

PRDS was delisted on the 30th of August, 2023.

Back to rankings

68 hedge funds and large institutions have $87.2M invested in Pardes Biosciences, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 15 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 15

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

8% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 12

1% less funds holding

Funds holding: 69 → 68 (-1)

39% less capital invested

Capital invested by funds: $144M → $87.2M (-$56.5M)

Holders
68
Holders Change
-1
Holders Change %
-1.45%
% of All Funds
1.17%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
11
Increased
23
Reduced
15
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$4.63M
2
TCM
Tang Capital Management
California
+$1.09M
3
BlackRock
BlackRock
New York
+$800K
4
BCM
Bridgeway Capital Management
Texas
+$634K
5
LCM
Lynx1 Capital Management
Puerto Rico
+$284K

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$1.59M
2
PHS
PFM Health Sciences
California
-$1.54M
3
SCM
Sio Capital Management
New York
-$969K
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$818K
5
IC
Ikarian Capital
Texas
-$687K
Name Holding Trade Value Shares
Change 		Change in
Stake
Russell Investments Group
51
Russell Investments Group
United Kingdom
$15K +$25.5K +8,536 New
SO
52
STRS Ohio
Ohio
$12K – – –
TRCT
53
Tower Research Capital (TRC)
New York
$10K -$6.26K -2,099 -27%
AB
54
Amalgamated Bank
New York
$8K +$1.59K +532 +15%
Legal & General Group
55
Legal & General Group
United Kingdom
$7K -$2.4K -804 -17%
Bank of America
56
Bank of America
North Carolina
$6K -$7.61K -2,553 -45%
Barclays
57
Barclays
United Kingdom
$4K -$118K -39,538 -95%
AIP
58
Ameritas Investment Partners
Nebraska
$3K – – –
National Bank of Canada
59
National Bank of Canada
Quebec, Canada
$2K – – –
APA
60
American Portfolios Advisors
New York
$1.85K – – –
Citigroup
61
Citigroup
New York
$1K -$3.76K -1,261 -71%
Royal Bank of Canada
62
Royal Bank of Canada
Ontario, Canada
$1K +$769 +258 +161%
Fidelity Investments
63
Fidelity Investments
Massachusetts
$1K +$960 +322 +233%
SCM
64
Sio Capital Management
New York
– -$969K -315,564 Closed
Point72 Asset Management
65
Point72 Asset Management
Connecticut
– -$818K -266,400 Closed
IC
66
Ikarian Capital
Texas
– -$687K -223,934 Closed
EC
67
EcoR1 Capital
California
– -$614K -200,000 Closed
HF
68
HRT Financial
New York
– -$202K -66,098 Closed
TCM
69
TCG Crossover Management
California
– -$181K -59,039 Closed
D.E. Shaw & Co
70
D.E. Shaw & Co
New York
– -$175K -57,072 Closed
BFM
71
Boothbay Fund Management
New York
– -$84K -27,457 Closed
DTL
72
Dynamic Technology Lab
Singapore
– -$37K -12,013 Closed
CSS
73
Cubist Systematic Strategies
Connecticut
– -$24K -7,800 Closed
PCM
74
Penserra Capital Management
California
– -$7K -2,360 Closed
CAPTRUST Financial Advisors
75
CAPTRUST Financial Advisors
North Carolina
– -$2K -742 Closed
1 2
3
4

PRDS Hedge Fund Activity: Q3 2022 in Review

68 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q3 2022, worth a combined $87.2M — down 39% from $144M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of PRDS and 11 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 23 added.

The largest buyer was Goldman Sachs, adding an estimated $4.63M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.59M.

  • 68 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q3 2022, down from 69 in Q2 2022.
  • Funds reported $87.2M of Pardes Biosciences, Inc. Common Stock stock for Q3 2022, down 39% quarter-over-quarter.
  • 11 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q3 2022 and 12 closed out, a net change of -1 holder.
  • The largest Pardes Biosciences, Inc. Common Stock buyer in Q3 2022 was Goldman Sachs, an estimated $4.63M added.
  • The largest Pardes Biosciences, Inc. Common Stock seller in Q3 2022 was T. Rowe Price Associates, an estimated $1.59M sold.

Based on aggregated 13F filings for Q3 2022.